Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
about
Molecular substratification of bladder cancer: moving towards individualized patient managementUnderstanding the molecular pathogenesis and prognostics of bladder cancer: an overviewEmerging critical role of molecular testing in diagnostic genitourinary pathologyMolecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancerIntegrative modelling of the influence of MAPK network on cancer cell fate decisionHigh-Throughput Approaches to the Development of Molecular Imaging Agents.Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosisPredicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis.CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.Generation of a concise gene panel for outcome prediction in urinary bladder cancer.Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedureAssessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Tailoring to RB: tumour suppressor status and therapeutic response.Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patientsThe differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladderGinsenoside Rg3 Inhibits Constitutive Activation of NF-κB Signaling in Human Breast Cancer (MDA-MB-231) Cells: ERK and Akt as Potential Upstream Targets.Expression profiling for bladder cancer: strategies to uncover prognostic factors.Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinomaExpression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinomaN‑Myc downstream‑regulated gene 2 suppresses the proliferation of T24 human bladder cancer cells via induction of oncosis.Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis.Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.Significant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma.Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins.Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.Advances in gas chromatographic methods for the identification of biomarkers in cancer.Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cellsTargeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell linesMolecular therapy in urologic oncology.
P2860
Q26744343-F43E19E7-4767-47D5-A07D-2B48FA945AAAQ26752921-CCF9AFB1-6DF2-495A-8ED9-13C6CD657A30Q27021371-C9988784-F67A-4E67-ADBF-070346D7BB96Q28076041-3CFBBEA9-3CDC-44EF-9A95-E08FF5906C4FQ28534949-FB7402F8-7D61-457B-8F20-4B368BBE2B8CQ30275493-4B65CBE8-EB5B-4902-9A03-0DD3AF53845DQ30439612-6D44F8A0-38B7-4A5D-9E21-6A273FEF5AE7Q30446429-2EB32600-27C5-438D-8B9E-19DF3479F78CQ30857433-E5CB5B35-0800-48F9-BB33-45CAA95A605AQ30930265-E7632175-FAA3-4E82-AA1E-6885F350FFB6Q31120339-72A3599D-D078-4234-B4B6-BAAC1A60978FQ33325737-BBC95484-8089-45CC-A16C-F87FB6797912Q33561596-1E9D34D8-337D-4464-B599-CFFF34F7A310Q33687975-7DA5646C-0893-4B44-A781-87D2CD7456D8Q33689126-88CD7AB2-C36E-4309-A781-51F786339806Q33751191-CC40D5F9-C282-4E87-AA83-052AC1FA738EQ33917646-A376C214-C89B-47B5-9C11-42568662C10EQ33923405-871B214B-A807-4FC3-84E4-1DEB7F210DCDQ34040108-EF6AA0B6-2A26-4E2E-BBA6-8BE3CBFC0D57Q34042341-A5FE52F3-2D59-43B6-AF96-6FA7E18DB5CEQ34078717-8D021AA8-77EA-4F24-BD50-E182AA1E80AEQ34305486-CD73DC1C-6D89-4F5A-87B8-887F5A7CB853Q34537170-180E0CAA-8F2C-49FB-A0B3-B4878A608AEEQ34717001-3170A07E-BEC2-47F6-8FFB-4CF4144F1FBCQ34866510-04894060-5445-447D-96BC-95A6B16BD750Q35063395-848B8009-F877-4032-8508-0D7E7AA58284Q35406476-4A4BF619-277E-4161-9EB3-71F9C16EF07CQ35736249-97FEAC21-7411-4CC6-83FD-C41B6EE9A8F2Q35858355-2B460D6E-7B2C-4242-8257-21E9C2BE0FE4Q35864528-D494CE8A-9199-44E4-BE6A-536BB67D5DF9Q35865635-3091B802-57EF-41AA-AFF6-981BD87EC09CQ35909661-1AF4B94A-781C-43C0-A469-AFF16419C4A9Q36144821-187E4078-B90C-44DF-BF6F-CE73FC920F60Q36316592-1E31BDEE-44CA-4074-AB33-35EE1ED50A12Q36345733-EFA7E09B-4D5B-4B43-B482-B513883B7115Q36430196-B8C4BA29-B306-4D1F-AFA3-4EA0B3465E48Q36589325-338E4DE6-13EB-4101-8FC3-983C1695EEA2Q36591517-F188A2BB-9E22-4DE2-8E84-81FA07DFA421Q36643088-BAE2D985-0771-47FC-8F33-D4C0E18B168EQ36878961-DB05B7C1-7121-4F63-95BA-BC984121D776
P2860
Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Molecular pathways in invasive ...... on, and target identification.
@ast
Molecular pathways in invasive ...... on, and target identification.
@en
type
label
Molecular pathways in invasive ...... on, and target identification.
@ast
Molecular pathways in invasive ...... on, and target identification.
@en
prefLabel
Molecular pathways in invasive ...... on, and target identification.
@ast
Molecular pathways in invasive ...... on, and target identification.
@en
P2093
P356
P1476
Molecular pathways in invasive ...... on, and target identification.
@en
P2093
Anirban P Mitra
Ram H Datar
Richard J Cote
P304
P356
10.1200/JCO.2006.08.2073
P407
P577
2006-12-01T00:00:00Z